Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
1999-09-20
2002-06-11
Badio, Barbara P. (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
active
06403816
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to novel betulinic acid derivatives and a composition containing betulinic acid derivatives, processes for preparation of such betulinic acid derivatives and method of treatment of tumor and such proliferative disease using these derivatives. This invention also relates to the use of the novel betulinic acid derivatives for inhibiting and/or preventing tumor associated angiogenesis, more specifically angiogenesis associated with prostate, lung, ovary and colon cancers.
BACKGROUND OF THE INVENTION
Betulinic acid is a pentacyclic triterpene. It can derived from several natural (botanical) sources. It can also be chemically derived from betulin, a substance found in abundance in the outer bark of white birch trees (Betula alba). Betulinic acid has been found to selectively kill human melanoma cells (Nature Medicine, Vol.1(10),1995, WO 96/29068). The cytotoxic potential of betulinic acid was tested using three human melanoma cell lines, Mel-1, Mel-2, and Mel-4. The growth of all the cell lines was inhibited significantly by treatment with betulinic acid. The effectiveness of betulinic acid against melanoma cancer cells was also tested using athymic mice. It seems to work by inducing apoptosis in cancer cells.
The anti-cancer activity of betulinic acid and some of its derivatives has also been demonstrated using mouse sarcoma 180 cells implanted s.c. in nude mouse (JP 87,301,580), inhibition of growth of p388 lymphocytic leukemia cells in vitro (Choi.Y-H et al., Planta Medica Vol.XLVII,511-513,1988) and inhibiting growth of cancer cells, particularly by inhibiting ornithine decarboxylase (Yasukawa, K et al, Oncology 48:72-76,1991; WO 95/04526).
Recently, the applicants reported anti-leukemia and anti-lymphoma activity and anti-prostate, anti-lung and anti-ovarian cancer activity of betulinic acid and its derivatives with ED
50
values less than 4.0 &mgr;g/ml. (U.S. application Ser. No. 09/040,856 filed on Mar. 18, 1998 and U.S. application Ser. No. 09/251,309 filed on Feb. 17, 1999). Further, antiangiogenic activity of betulinic acid and its derivatives was recently reported by the applicants in U.S. application Ser No. 09/166,809 filed on Oct. 06, 1998 wherein betulinic acid and its derivatives were shown to inhibit the formation of tube-like-structures (TLS) of endothelial cells when grown on Matrigel coated surface. The endothelial cell anti-proliferative activity along with anti-TLS activity was shown to suggest the anti-angiogenic activity of betulinic acid derivatives.
Anderson et al (WO 95/04526) disclose that for certain cancers to spread throughout a patients' body, a process termed metastasis, cell-cell adhesion must take place. Specifically, cancer cells must migrate from their site of origin and gain access to blood vessel to facilitate colonization at distant sites. Certain cancer cells are known to adhere to E-Selectin via E-Selectin ligands on their cell surface and this event is one component of the metastasis process. Betulinic acid and its derivatives interfere with Selectin binding. Betulinic acid inhibited P-Selectin binding to 2,3, sLex, a chemical known: to bind to P-Selectin, with an IC
50
of 125 uM. Also it inhibited P-Selectin binding HL-60 cells in a dose-dependent way with an IC
50
of 0.75 mM. Betulinic acid and derivatives also significantly interfere with the binding to colon cancer cells, LS174T to E-Selectin.
Dasgupta et al (WO 96/29068) disclosed a method and composition for inhibiting tumor growth using the active compound betulinic acid. The invention provides a method and composition for inhibiting tumor growth and, particularly, for inhibiting growth of melanoma using a natural product derived compound. The invention also provides a treatment method using betulinic acid to prevent growth or spread of cancer cells, wherein betulinic acid is applied in a topical preparation.
Pezzuto et al (U.S. Pat. No. 5,869,535) disclose method and composition for probes inhibiting tumor growth using betulinic acid or a derivative thereof. Betulinic acid has been isolated from stem bark of
Ziziphzus mauritiana
, by mediating a selective cytotoxic profile against human melanoma in a subject panel of human cancer cell lines, conducting a bioassay directed fractionation based on the profile of bioactivity using cultured human melanoma cells (MEL-2) as the monitor, and betulinic acid has been obtained therefrom as the active compound. The resulting betulinic acid can be used to inhibit tumor growth or can be converted to a derivative to prevent which prevents or inhibits tumor growth. The invention also provides a treatment method using betulinic acid to present the growth or spread of cancerous cells, wherein betulinic acid or derivatives thereof is applied in a topical preparation. Betulinic acid was found to inhibit in vitro growth of MEL-2 cells. However, none of the other cell lines tested [A431 (squamous cells), BC-1 (breast), COL-2 (colon), HT1080 (sarcoma), KB (human oral epidermoid carcinoma), LNCaP (prostate), LU-1 (lung), U373 (glioma) and ZR-75-1 (breast)] were affected by betulinic acid (ie., ED
50
values of greater than 20 &mgr;g/ml).
Lee et al (WO 96/39033) disclose betulinic acid and dihydrobetulinic acid acyl derivative to have potent anti-HIV activity. The C
3
-hydroxy, C
17
-carboxylic acid and C
20
-exomethylene groups have been modified. Anti-HIV assays indicate potent anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives in acutely infected H9 lymphocytes with EC
50
values of less than 1.7×10
−5
&mgr;M respectively.
OBJECTS OF THE INVENTION
The invention provides a method of treating angiogenesis by administering a pharmaceutically effective dosage of betulinic acid derivatives. This invention also provides for novel betulinic acid derivatives and compositions containing them with pharmaceutically acceptable additives, diluents, carriers and excipients with or without betulinic acid.
Another object of the invention relates to providing novel betulinic acid derivatives, which are used for inhibiting angiogenesis.
Another object of the invention is to provide a compound and compositions for treating, inhibiting and/or preventing angiogenesis using a natural product-derived compound and its derivatives.
Another object of the invention is to provide a treatment method using betulinic acid derivatives to inhibit angiogenesis, wherein the derivatives are administered systemically.
Yet another object of the invention is to overcome the problem of high toxicity associated with standard antiangiogenic chemotherapeutic agents by using a natural product-derived compound, e.g., betulinic acid or its derivatives.
Still another object of the invention is to overcome the problem of insufficient availability associated with synthetic antiangiogenic anticancer agents by using readily available semisynthetic derivatives of betulinic acid.
Another object of the invention is to overcome the problem of high costs of synthetic antiangiogenic agents by utilizing the readily available natural product derived compound. e.g. betulinic acid and its derivatives which is expected to be less expensive than other chemotherapeutic drugs.
These and other objects of the present invention will become apparent from the description of the invention disclosed below, which descriptions are intended to limit neither the spirit or scope of the invention but are only offered as illustrations of the preferred embodiments of the invention.
SUMMARY OF THE INVENTION
The above objects and others have been achieved by providing novel betulinic acid derivatives of formulae 1 and 2 which are described in the present description.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a pharmaceutical composition useful for preventing/inhibiting angiogenesis. Betulinic acid derivatives inhibit endothelial cell proliferation and exhibiting high endothelial cell specificity thereby specifically targeting endothelial cells. The derivatives also inhibit the formation of tube-like-structur
Jaggi Manu
Rajendran Praveen
Ramadoss Sunder
Siddiqui Mohammad Jamshed Ahmad
Badio Barbara P.
Dabur Research Foundation
Ladas & Parry
LandOfFree
Betulinic acid derivatives having antiangiogenic activity,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Betulinic acid derivatives having antiangiogenic activity,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Betulinic acid derivatives having antiangiogenic activity,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2932873